Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Esophageal Cancer Clinical Trials

A listing of Esophageal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (67) clinical trials

Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer

Open-label, multi-center, controlled, randomized, parallel-group phase II trial in patients with metastatic esophagogastric cancer having received induction chemotherapy. Patients will be registered before or after application of a three-months induction chemotherapy . This 12-week induction therapy will consist of one of the following regimens: FLO/mod. Folfox-6, Cisplatin/5-FU, Cisplatin/S-1, FLOT, EOX/EOF ...

Phase

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

OUTLINE: This is a multi-center trial. INVESTIGATIONAL TREATMENT: Subjects will receive durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence. The following baseline labs must be completed within 28 days prior to registration for protocol therapy: ...

Phase

Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

60 patients of esophageal cancer with TNM stage of tumor stage II-III,who had received surgery and kept their tumor tissue, will be randomly divided into group A (receive cancer tissue antigen sensitized D-CIK immune cells in combination with chemotherapy treatment) or group B (just receive chemotherapy), and the randomize ratio ...

Phase

Study of Apatinib in Metastatic Esophageal Cancer

Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.

Phase

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib) A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor In Asian Participants With Advanced Non-Small-Cell Lung Cancer Urothelial Cancer Esophageal Cancer Or Cholangiocarcinoma

This is an open-label (all people know the identity of the intervention), multicenter, phase 2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in Asian participants with advanced NSCLC, urothelial cancer, esophageal cancer and cholangiocarcinoma.

Phase

Genetic Predictors of Benefit to Pembrolizumab

This will be a 3-arm, multi-center, open-label, non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may receive either cohorts 1 and 2. ...

Phase

A Study of Patients Receiving High-Dose Rate Brachytherapy

BACKGROUND High dose rate brachytherapy (HDR) is a challenging technique utilized in many malignancies in order to deliver a high dose of radiation therapy to a tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue HDR therapy has been targeted to ...

Phase

Combination Chemotherapy and Bevacizumab in Treating Patients With Recurrent Unresectable or Metastatic Gastric Cancer Gastroesophageal Junction Cancer or Esophageal Cancer

OBJECTIVES: Primary - Determine the efficacy of combination chemotherapy comprising modified docetaxel, cisplatin, fluorouracil, and leucovorin calcium with bevacizumab, as measured by 6-month progression-free survival (PFS), in patients with locally recurrent, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Secondary - Determine the safety of this regimen in these ...

Phase

S-1 Cisplatin and Radiation Therapy in Treating Patients With Stage IIA Stage III or Stage IVA Esophageal Cancer That Can Be Removed by Surgery

OBJECTIVES: Primary - To evaluate response rate in patients with stage IIA-IVA resectable esophageal cancer treated with chemoradiotherapy comprising S-1, cisplatin, and radiotherapy. Secondary - To evaluate overall survival of these patients. - To evaluate progression-free survival of these patients. - To evaluate toxicity in these patients. - To correlate ...

Phase